Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20539296 | 0.77 | EPHX2 (0.37) | CA2CYP2D6CYP2C19 | |
| SCHEMBL26607884 | 0.75 | CA1 (0.50) | CA1CA2ALDH1A1HPGD | |
| SCHEMBL92830 | 0.74 | CA1 (0.44) | CA1CA2ALDH1A1HPGD | |
| SCHEMBL20744203 | 0.72 | CA1 (0.42) | CA1CA2ALDH1A1HPGD | |
| SCHEMBL12478349 | 0.72 | CA1 (0.42) | CA1CA2ALDH1A1HPGD | |
| SCHEMBL16508793 | 0.71 | HDAC3 (0.44) | CA1CA2ALDH1A1 | |
| SCHEMBL12304211 | 0.69 | ALDH1A1 (0.45) | CA1CA2ALDH1A1HPGD | |
| SCHEMBL15925034 | 0.69 | CA1 (0.44) | CA1CA2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL16181432 | 0.68 | ALDH1A1 (0.43) | CA1CA2ALDH1A1HPGD | |
| SCHEMBL19630967 | 0.67 | CA1 (0.41) | CA1CA2ALDH1A1HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3612525-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195321-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CA1 2682/4885CA2 3721/4885ALDH1A1 104/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CA1 2682/4885CA2 3721/4885ALDH1A1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.